GRWD-5769 by Grey Wolf Therapeutics for Solid Tumor: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GRWD-5769 overview

GRWD-5769 is under development for the treatment of solid tumors including head and neck squamous cell carcinoma, cervical cancer, and hepatocellular carcinoma. It acts by targeting endoplasmic reticulum aminopeptidase 1 (ERAP1). It is administered through oral route.

Grey Wolf Therapeutics overview

Grey Wolf Therapeutics, a drug discovery biotechnology company focused on immuno-oncology.

For a complete picture of GRWD-5769’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.